The biotech company, focused on developing treatments for chronic eye conditions, received Food and Drug Administration (FDA) ...
Opthea's sozinibercept and Unity's UBX1325 fail to match Regeneron's Eylea in separate eye disease trials; Opthea faces ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback